Sipavibart

DB21908ApprovedInvestigationalProtein Based Therapies

Sipavibart is a monoclonal antibody used to prevent COVID-19 in immunocompromised patients. Sipavibart is a recombinant human IgG1 monoclonal antibody that is long-acting.

Mechanism: Sipavibart binds to the spike protein RBD of SARS-CoV-2 (BA.2) with the equilibrium dissociation constant (KD) of 20.95 pM, blocking RBD binding to the human ACE2 receptor. This results in a blockade of virus entry.
Curator reviewed · 1 reference
Primary indication: Sipavibart is indicated for the pre-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older weighing at least 40 kg and who are immunocompromised due to a medical condition or receipt...Curator reviewed · 2 structured indications
Formula / weight: C₆₄₃₀H₉₈₆₄N₁₇₀₄O₂₀₂₂S₄₀ · 144690.0 Da (approximate and unglycosylated)
First approval: Canada, 2025 · European Union, 2025
Also known as: Gamma1 heavy chain Homo sapiens (1-455) [VH (Homo sapiens IGHV3-9*01 (94.9%) -(IGHD) -IGHJ1*01 (90.9%) L123>T (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125) -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, IGHG1v39 CH2 F1.3, E1.2, S116 · Immunoglobulin G1 [242-phenylalanine,243-glutamic acid,260-tyrosine,262-threonine,264-glutamic acid,339-serine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal AZD3152 ?1-chain), disulf · Immunoglobulin G1-lambda, anti-[Homo sapiens severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein, receptor binding domain (RBD)], Homo sapiens monoclonal antibody
Code names: AZD-3152 · RQ043